Usually, if luminal B is HER2-negative, the expression of PR is low to none (<20%) and the biomarker Ki-67 is highly expressed (≥20%), but if the luminal B cancer is HER2-positive, the levels of PR and Ki-67 varies [59,81]. The gene discussed is ERBB2; the disease is cancer.